Congestive Heart Failure (CHF) Market Report 2026

Congestive Heart Failure (CHF) Market Overview

• Congestive Heart Failure (CHF) market size has reached to $17.1 billion in 2025 • Expected to grow to $23.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Rising Cardiovascular Cases Fuel Demand For Advanced Heart Failure Solutions • Market Trend: Advancing Gene Therapy For Congestive Heart Failure With Precision Treatments • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Congestive Heart Failure (CHF) Market?

Congestive heart failure (CHF) is a chronic and progressive condition where the heart's ability to pump blood effectively is compromised, leading to a backup of fluid in the lungs, heart, liver, and other parts of the body, causing symptoms such as shortness of breath, fatigue, swelling, and difficulty in performing daily activities, ultimately impacting the overall quality of life and requiring ongoing medical management and treatment. The main types of congestive heart failure (CHF) include systolic heart failure, diastolic failure, left-sided heart failure, and right-sided heart failure. Systolic heart failure occurs when the heart muscle's ability to pump blood is impaired, resulting in inadequate blood circulation. The various treatments include medication and surgery with various diagnostic methods such as electrocardiogram, echocardiogram, magnetic resonance imaging (mri), stress test, blood tests, cardiac catheterization, other diagnosis. These are distributed through various distribution channels such as hospital pharmacy, online pharmacy, retail pharmacy that are used by various end-users such as hospitals, specialty clinics, ambulatory surgical centers, homecare settings.

What Is The Congestive Heart Failure (CHF) Market Growth Forecast?

The congestive heart failure (chf) market size is expected to see strong growth in the next few years. It will grow to $23.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing heart failure prevalence, improved diagnostic accuracy, growth of homecare settings, rising adoption of guideline-based therapies, focus on reducing hospital readmissions. Major trends in the forecast period include rising adoption of combination drug therapies, shift toward home-based heart failure management, increasing focus on early diagnosis and monitoring, growth in chronic disease management programs, expansion of post-discharge care pathways.

Global Congestive Heart Failure (CHF) Market Segmentation

1) By Type: Systolic Heart Failure, Diastolic Heart Failure, Left-Sided Heart Failure, Right-Sided Heart Failure 2) By Treatment: Medication, Surgery 3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings Subsegments: 1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction 2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF) 3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure 4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure

What Is The Driver Of The Congestive Heart Failure (CHF) Market?

The increase in cardiovascular patients is expected to propel the growth of the congestive heart failure (CHF) market going forward. Cardiovascular refers to the heart and blood vessels, focusing on their role in circulating blood and maintaining the body's overall health. The rise in cardiovascular patients is due to sedentary lifestyles, unhealthy diets, ageing populations, and urbanization, leading to a higher need for advanced healthcare and treatment solutions. Congestive heart failure (CHF) is helpful for cardiovascular patients by providing targeted solutions that improve heart efficiency, reduce symptoms, and prevent complications, ultimately enhancing patient care and overall well-being. For instance, in January 2023, according to the American College of Cardiology, a US-based nonprofit medical society, cardiovascular disease cases rose to 19.8 million in 2022. Additionally, Eastern Europe has the highest mortality rate at 553 deaths per 100,000. Therefore, the increase in cardiovascular patients is driving growth in the congestive heart failure (CHF) industry.

Key Players In The Global Congestive Heart Failure (CHF) Market

Major companies operating in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic Plc, Canon Medical Systems Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova Plc, Edwards Lifesciences Corporation, Getinge AB, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, OSCOR Inc., Shree Pacetronix Ltd.

Global Congestive Heart Failure (CHF) Market Trends and Insights

Major companies operating in the congestive heart failure (CHF) market are focusing on advanced innovations, such as single intracoronary infusion therapies to offer effective treatment options that improve heart function and enhance the quality of life for CHF patients. Single intracoronary infusion delivers medication directly into the coronary artery, targeting the heart to provide precise treatment for conditions like congestive heart failure (CHF). For instance, in January 2024, Bayer AG, a Germany-based pharmaceutics company, and Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, initiated the GenePHIT Phase II trial for AB-1002, an investigational gene therapy for congestive heart failure (CHF). This innovation utilizes a gene therapy approach to target non-ischemic cardiomyopathy, offering a potential breakthrough in the treatment of CHF through advanced genetic solutions. The trial is adaptive, double-blind, placebo-controlled, and will enroll between 90 and 150 participants who have been medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.

What Are Latest Mergers And Acquisitions In The Congestive Heart Failure (CHF) Market?

In October 2024, Johnson & Johnson a US-pharmaceutical company acquired V-Wave Ltd. for an undisclosed amount. This acquisition enables Johnson & Johnson to expand its MedTech portfolio in cardiovascular care, specifically addressing heart failure with the novel Ventura Interatrial Shunt. V-Wave Ltd. is an Israel-based company focused on developing innovative treatment options for patients with congestive heart failure.

Regional Outlook

North America was the largest region in the congestive heart failure (CHF) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Congestive Heart Failure (CHF) Market?

The congestive heart failure (CHF) market consists of revenues earned by entities by providing cardiac treatment, hemodynamic monitoring, and therapeutic services. The market value includes the value of related goods such as diagnostic tools, monitoring devices, and support services. The congestive heart failure (CHF) market also includes sales of diagnostic tools, and testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Congestive Heart Failure (CHF) Market Report 2026?

The congestive heart failure (chf) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the congestive heart failure (chf) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.